Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 655
- Registration Number
- NCT00971165
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre, RS, Brazil
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 77
- Registration Number
- NCT00953680
Olmesartan Comparison to Losartan in Hypertensive Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 941
- Registration Number
- NCT00949884
The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 13
- Registration Number
- NCT00943852
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension
- Conditions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 320
- Registration Number
- NCT00942344
- Locations
- 🇰🇷
14 sites in Korea, Seoul, Busan, etc., Korea, Republic of
Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2009-07-16
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 142
- Registration Number
- NCT00940680
- Locations
- 🇰🇷
9 sites in Korea, Seoul, Daegu, etc., Korea, Republic of
MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 428
- Registration Number
- NCT00888355
A Study to Investigate the Antihypertensive Efficacy of MK0954
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 366
- Registration Number
- NCT00887250
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 122
- Registration Number
- NCT00886600
A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
- Conditions
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 576
- Registration Number
- NCT00882440
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.